Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2005
05/24/2005CA2326076C Novel macrolides
05/24/2005CA2133316C In vitro generation of human dendritic cells and uses thereof
05/24/2005CA2133144C Vitamin d3-analogs
05/24/2005CA2109259C Prodrugs, their preparation and use as pharmaceuticals
05/19/2005WO2005044820A1 Novel chelidonine derivatives, methods for the production thereof, and use thereof for producing pharmaceutical agents
05/19/2005WO2005044275A1 Use
05/19/2005WO2005014576A8 Isoquinolinone derivative, process for producing the same and use thereof
05/19/2005WO2005012361A3 Antibodies raised against colon carcinomas
05/19/2005WO2005007079A3 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth
05/19/2005WO2004111075A8 Alternative reading frame polypeptides for treatment
05/19/2005WO2004106934A3 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
05/19/2005WO2004039244A3 Methods and kits for diagnosing tumorigenicity
05/19/2005WO2004016764A3 eNOS MUTANTS USEFUL FOR GENE THERAPY
05/19/2005WO2003049678A3 Mitotic kinesin inhibitors
05/19/2005WO2003014703A3 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
05/19/2005WO2003009815A3 Compositions and methods for modulating blood-brain barrier transport
05/19/2005WO2002069893A3 Treatment of neurological disease
05/19/2005US20050108785 Using nuclear transplantation as tool in generating transgenic cells for treatment and prevention of liver, nervous system, cardiovascular and bone disorders; regenerative medicine
05/19/2005US20050108784 Expression vector comprising nucleotide sequences coding spinocerebellar ataxia-1 gene for use in treatment and prevention of nervous system disorders
05/19/2005US20050107605 Novel beta-lactams methods for the preparation of taxanes, and sidechain-bearing taxanes
05/19/2005US20050107601 Nucleotide sequences coding immunoglobulin fusion specific to heparan sulfate proteoglycans for use as diagnostic and therapeutic tool in treatment and prevention of neurodegenerative and cell proliferative disorders
05/19/2005US20050107543 Fluoro linkers and their use as linkers for enzyme-activated drug conjugates
05/19/2005US20050107472 administering vitamin k derivatives for prophylaxis of neurodegenerative diseases associated with protein aggregation or neurofibrillary tangles
05/19/2005US20050107464 Antitumor agent containing lactic acid oligomer mixture
05/19/2005US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors
05/19/2005US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto
05/19/2005US20050107450 administering Peroxisome Proliferator Activated Receptors (PPAR-gamma) activators according to a dosage schedule which comprises a cycle of less than daily administration
05/19/2005US20050107445 Active compounds with carbamic acid for diseases such as cancer, leukemia, atheriosclerosis, alzheimers disease or arthritis
05/19/2005US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders
05/19/2005US20050107421 Nitrogen compounds such as 2-Butyl-1-(2-methylpropyl)-1H-tetrazolo[1,5-a]imidazo[4,5-c][1,8]naphthyridine, used to induce biosynthesis of cytokines such as interferons and tumor necrosis factors, or for prophylaxis of viral diseases
05/19/2005US20050107418 Macrolides
05/19/2005US20050107416 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators
05/19/2005US20050107413 pyrimidine derivatives such as 4-Chloro-5,6-diphenyl-2-(trifluoromethyl)pyrimidine, used for the treatment of inflammation and immunological diseases
05/19/2005US20050107406 Angiogenesis inhibitors
05/19/2005US20050107404 Mitotic kinesin inhibitors
05/19/2005US20050107403 Carbonylpyridine or carbonylpyrimindine compounds containing another nitrogen containing ring; useful in the treatment of inflammatory, metabolic or malignant conditions
05/19/2005US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC
05/19/2005US20050107379 antithrombolytic agents such as (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide, used for therapy of cardiovascular disorders
05/19/2005US20050107372 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators
05/19/2005US20050107367 2-(morpholin-4-yl)-6-phenyl-thiopyran-4-one; treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK
05/19/2005US20050107363 administering to mammals drugs such as 5,10-dihydro-4,6,8-trihydroxy-10-(3,7,11-trimethyl-trans-2,trans-6,10-dodecatrienyl)-11H-dibenzo[b,e][1,4]diazepin-11-one, as anticarcinogenic agents
05/19/2005US20050107346 Synergistic treatment, better effects on solid tumours; with a mixture of a platinum anticancer agents and a taxane, with ionizing radiation therapy
05/19/2005US20050107345 Aminoalkylphosphonates and related compounds as edg receptor agonists
05/19/2005US20050107340 Protein kinase modulators; cancer, diabetes, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, angiogenesis, immunological disease such as autoimmune disease (e.g., AIDS and lupus) and renal disease
05/19/2005US20050107337 Platinum complexes having antitumor activity
05/19/2005US20050107331 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
05/19/2005US20050107317 Nucleic acid molecule of the short-chain dehydrogenase gene family, an antibody, an aptamer or receptors, polypeptide encoded thereby; biodrug for treatment of metabolism of triglycerides, metabolic disorders as obesity, eating disorder, cachexia, diabetes mellitus, hypertension, heart disease
05/19/2005US20050107293 Protein modification and maintenance polypeptides (PMOD) for use as diagnostic and therapeutic tools in treatment of prevention of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, developmental, epithelial, neurological, and reproductive disorders
05/19/2005US20050107291 Compositions and methods for treating or preventing diseases of body passageways
05/19/2005US20050107290 Histone deactylase as enzyme inhibitor; anticancer agents
05/19/2005US20050106679 Leptin proteins
05/19/2005US20050106678 Human circulating cytokine CC-1
05/19/2005US20050106672 Neurotransmission associated proteins
05/19/2005US20050106658 Remodeling and glycoconjugation of peptides
05/19/2005US20050106638 Immunoglobulin for use in diagnosis, prevention and treatment of fibrosis and scarring; antiscarring agents
05/19/2005US20050106620 Novel ovarian tumor antigen (OVR107) for use in diagnosis, prognosis, classification and imaging of cell proliferative disorders
05/19/2005US20050106614 Reagents and methods useful for detecting diseases of the prostate
05/19/2005US20050106558 Generating viral expression vector comprising parvoviral structural genes for use as gene transfer and expression tool; treatment and prevention of infections, cell proliferative and autoimmune disorders
05/19/2005US20050106262 colon tumour, gastric tumour, mammary tumour, ovarian tumour, prostate tumour, and renal tumour
05/19/2005US20050106231 Liposome-entrapped topoisomerase inhibitors
05/19/2005US20050106212 Using electrochemical mixture of metal compound and bioactive material; contacting substrate
05/19/2005US20050106211 Fabrication of drug loaded biodegradable polymer fibers
05/19/2005US20050106158 Antigen mimotopes and vaccine against cancers
05/19/2005US20050106155 Solidified tissue immuoadjuvant
05/19/2005US20050106153 mixture of immunoadjuvant in neoplasm; applying stresses to destroy neoplastic tissue; administering immunomoderator ; in situ generation of autologous vaccine
05/19/2005US20050106152 Using protein antagonist; amino acid sequence; antisense nucleotide; inducing apoptosis
05/19/2005US20050106145 Anti-human tenascin monoclonal antibody
05/19/2005US20050106143 Collapsin response mediator protein; measurement of gene expression
05/19/2005US20050106140 Antagonistic anti-hfas ligand human antibodies and fragments thereof
05/19/2005US20050106136 Controlling capilalries, blood vessels in eye; vision defects
05/19/2005US20050106127 Graft to humans; culture product; removing cells; preservation
05/19/2005US20050106108 Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
05/19/2005US20050106102 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
05/19/2005US20050106099 Fusion proteins
05/19/2005DE19905501B4 Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels A method of producing a recombinant adeno-associated virus, as well as suitable means to this end use for the preparation of a medicament
05/19/2005CA2545166A1 Humanized anti-cd47 antibody
05/19/2005CA2544951A1 Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
05/19/2005CA2544949A1 Antagonist anti-cd40 monoclonal antibodies and methods for their use
05/19/2005CA2544948A1 Methods of therapy for cancers expressing the cd40 antigen
05/19/2005CA2544852A1 Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
05/19/2005CA2544368A1 Methods of therapy for b cell-related cancers
05/19/2005CA2544364A1 Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
05/19/2005CA2544214A1 Hla-dr-binding antigen peptide derived from wt1
05/19/2005CA2543923A1 Therapy via targeted delivery of nanoscale particles
05/19/2005CA2543489A1 Human anti il-15 antibody 146b7 inducing monocytes apoptosis, therapeutical uses thereof
05/19/2005CA2543485A1 Use of interferon-tau in medicine
05/19/2005CA2543115A1 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
05/19/2005CA2543003A1 Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer
05/19/2005CA2538218A1 Compositions of botanical extracts for cancer therapy
05/19/2005CA2534995A1 The use of plp with peg-rmetase in vivo for enhanced efficacy
05/18/2005EP1531153A1 Epothilone derivatives
05/18/2005EP1530969A1 Combination chemotherapy
05/18/2005EP1530724A2 Diagnosis and prevention of cancer cell invasion
05/18/2005EP1530720A2 Breast cancer eradication program
05/18/2005EP1530638A2 T-cell epitopes in staphylococcal enterotoxin b
05/18/2005EP1530632A2 Growth factor which acts through erb b-4 rtk
05/18/2005EP1530628A1 Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
05/18/2005EP1530586A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
05/18/2005EP1530584A2 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
05/18/2005EP1530574A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
1 ... 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 ... 2211